HOOKIPA Pharma Inc. (HOOK)
- Previous Close
0.7680 - Open
0.7575 - Bid 0.7305 x 100
- Ask 0.7732 x 200
- Day's Range
0.7382 - 0.7899 - 52 Week Range
0.4100 - 1.8500 - Volume
344,069 - Avg. Volume
806,234 - Market Cap (intraday)
75.825M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4800 - Earnings Date Aug 8, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.33
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-200 for the treatment of pembrolizumab which is in Phase 2 of clinical trial; HB-700, a preclinical development for treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers. Its lead product candidates are HB-400 for the treatment of Hepatitis B which is in Phase I of clinical trial and HB-500 for the treatment of HIV which is in Phase I of clinical trial. The company's preclinical stage products include HB-300 program for prostate cancer. It has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.
www.hookipapharma.comRecent News: HOOK
Performance Overview: HOOK
Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HOOK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HOOK
Valuation Measures
Market Cap
75.58M
Enterprise Value
-11.09M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.54
Price/Book (mrq)
0.72
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-88.73%
Return on Assets (ttm)
-20.19%
Return on Equity (ttm)
-50.55%
Revenue (ttm)
53.55M
Net Income Avi to Common (ttm)
-47.52M
Diluted EPS (ttm)
-0.4800
Balance Sheet and Cash Flow
Total Cash (mrq)
92.75M
Total Debt/Equity (mrq)
5.82%
Levered Free Cash Flow (ttm)
-52.98M
Research Analysis: HOOK
Company Insights: HOOK
HOOK does not have Company Insights